Oric Pharmaceuticals, Inc. SEC Filings

Oric Pharmaceuticals director and CEO Chacko Jacob reported the sale of 37,461 shares of ORIC common stock on 10/06/2025. The filing shows the shares were sold under a Rule 10b5-1 trading plan adopted on 06/21/2025 at a weighted average price of $12.32 (range $12.07–$12.59). After the reported sale, the reporting person beneficially owned 531,419 shares directly; the filing separately discloses 178,667 RSUs and 3,378,000 stock options previously reported on Table II and not included in that total. The Form 4 was signed by an attorney-in-fact on 10/08/2025.

Oric Pharmaceuticals, Inc. filed a Form 144 reporting a proposed sale of 50,000 common shares through J.P. Morgan Securities LLC on 10/06/2025. The filing lists an aggregate market value of $725,000 and shows 97,122,987 shares outstanding, indicating the block represents a small fraction of total outstanding stock. The securities were acquired the same day via a stock option exercise and payment was made in cash. No sales by the same person were reported in the prior three months. The filer certifies they are not aware of undisclosed material adverse information and includes the standard signature attestation under penalty of law.

Chacko Jacob, President and CEO and a director of Oric Pharmaceuticals, sold 125,000 shares of the company's common stock on September 22, 2025 under a Rule 10b5-1 trading plan. The reported weighted average price for the aggregate sale was $10.7995, with the shares sold in a range of $10.57 to $10.92. After the sale, the reporting person beneficially owned 656,419 shares of common stock directly. The filing also discloses outstanding equity awards not included in that total: 178,667 RSUs and stock options to purchase 3,378,000 shares, which were previously reported on Table II.

Oric Pharmaceuticals, Inc. notice reports a proposed sale of 250,000 common shares through J.P. Morgan Securities LLC on 09/22/2025 with an aggregate market value of $2,625,000. The issuer has 97,122,987 shares outstanding, making the offered amount a small fraction of total shares. The filer states the 250,000 shares were acquired in an open market purchase on 05/11/2022 and were paid for in cash. The filing reports no securities sold in the past three months and includes the seller's certification regarding absence of undisclosed material adverse information.

Viking Global and affiliated entities report a passive 9.99% position in Oric Pharmaceuticals (ORIC). The Schedule 13G/A shows Viking Global Investors LP and related funds and entities collectively beneficially own 8,729,345 shares of Oric common stock on a fully reported basis, equal to 9.99% of 85,224,191 shares outstanding (May 29, 2025 basis). Holdings arise from directly owned common stock plus pre-funded warrants exercisable for additional shares, but exercise is limited by a contractual "Blocker" that caps beneficial ownership at 9.99% (adjustable up to 19.99% with notice). Ownership is held through VGOP and VGOD (detailed share and warrant counts provided), VGI provides managerial services and has shared voting/dispositive authority, and three named executives are disclosed as having shared authority. The filing certifies the stake is not intended to influence control.

ORIC Pharmaceuticals Schedule 13G/A reports that Nextech Crossover I SCSp and related reporting persons beneficially own 7,162,637 shares of ORIC common stock, representing 8.4% of the outstanding class based on 85,225,191 shares. Nextech Crossover I GP S.a. r.l. is the general partner of Nextech Crossover I SCSp and Nextech principals Ian Charoub, Costas Constantinides and Rocco Sgobbo have voting and dispositive power over the shares. The filing states the position is not held to influence control of the issuer.

ORIC Pharmaceuticals reported continued clinical progress while strengthening its balance sheet. Cash, cash equivalents and investments totaled $327.7 million as of June 30, 2025, and management believes available resources are sufficient to fund operations into the second half of 2028. The company reported a net loss of $66.4 million for the six months ended June 30, 2025 and an accumulated deficit of $629.2 million.

Clinical updates include ORIC-944 combination data showing a 59% PSA50 response rate (47% confirmed) and 24% PSA90 (all confirmed) in mCRPC, and ORIC-114 advancing with provisional RP2D levels of 80 mg and 120 mg and reported intracranial activity. Financing activity included a $125.0 million private placement closed May 29, 2025, ATM proceeds of $8.9 million through June 30, 2025 and subsequent ATM net proceeds of approximately $108.7 million through August 12, 2025. On August 12, 2025, the company announced a strategic pipeline prioritization that will eliminate its discovery research group, reduce workforce by approximately 20% and incur an estimated one-time cost of $1.9 million.

ORIC Pharmaceuticals issued a press release reporting results for the quarter ended June 30, 2025 and announced a strategic pipeline prioritization to concentrate resources on its two lead clinical programs, ORIC-944 and ORIC-114. As part of the refocus, the company will eliminate its discovery research group, reducing headcount by approximately 20%.

The company expects a one-time charge of approximately $1.9 million, primarily for termination and healthcare-related benefits, with the workforce reduction substantially complete and the majority of related charges to be recognized in the third quarter of 2025. The company noted these estimates are subject to assumptions and may change.